Amgen completed a Phase 1 clinical trial for its obesity drug candidate, MariTide (maridebart cafraglutide or AMG 133). The study evaluated how the drug absorbs when administered through two different under-the-skin injection formats.
The trial confirmed both delivery methods provide comparable drug exposure. This ensures dosing flexibility and supports a patient-friendly device for commercial rollout. Amgen positions MariTide as a monthly or less frequent injection, offering a potential advantage over weekly competitors.
This update signals steady advancement for MariTide. The drug is a cornerstone of Amgen's pipeline and a key contender in the obesity treatment market. MariTide is currently in late-stage development, with previous studies demonstrating significant weight loss.